Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 (COVLA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04452604|
Recruitment Status : Not yet recruiting
First Posted : June 30, 2020
Last Update Posted : June 30, 2020
The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia.
The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.
|Condition or disease|
|Acute Myeloblastic Leukemia Acute Lymphoblastic Leukemia SARS-CoV-2|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||National Retrospective Monitoring of Patients With Acute Leukemia Infected by COronaVirus Disease 2019 (COVID-19)|
|Estimated Study Start Date :||August 1, 2020|
|Estimated Primary Completion Date :||August 1, 2023|
|Estimated Study Completion Date :||December 1, 2023|
- Clinical prognostic factors for infection with COVID-19 [ Time Frame: Day 0 ]Factors associated with overall survival will be analyzed : center, sex, leukemia subtype, previous treatment by corticosteroids, and comorbidities (respiratory, renal, cardiac, weight, diabetes)
- Biological prognostic factors for infection with COVID-19 [ Time Frame: Day 0 ]neutrophils and lymphocytes count at the time of SARS-COV2 infection
- Medical care of Coronavirus infection [ Time Frame: within 12 months after diagnosis ]Describe the management carried out concerning coronavirus infection and its impact of the treatment of acute leukemia (non-invasive ventilation, orotracheal intubation, vasopressor requiring, treatments used, cause of death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04452604
|Contact: Pierre-Yves DUMAS, Dr||0557656514 ext email@example.com|
|Contact: Sarah BERTOLI, Drfirstname.lastname@example.org|
|Principal Investigator:||Pierre-Yves DUMAS, Dr||French Innovative Leukemia Organisation|